1990-2019年中国非霍奇金淋巴瘤疾病负担分析  

Analysis of the disease burden of non-Hodgkin lymphoma in China from 1990 to 2019

作　　者：肖慧 吴凡[1] 安福润 翟志敏[1] XIAO Hui;WU Fan;AN Furun;ZHAI Zhimin(Department of Hematology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,P.R.China)

机构地区：[1]安徽医科大学第二附属医院血液内科,合肥230601

出　　处：《中国循证医学杂志》2023年第8期880-886,共7页Chinese Journal of Evidence-based Medicine

基　　金：国家自然科学基金项目(编号:81670179);安徽省科技重大专项基金(编号:201903a07020030)。

摘　　要：目的分析1990—2019年中国非霍奇金淋巴瘤(NHL)疾病负担情况及发展变化趋势。方法利用2019全球疾病负担数据库,分析NHL发病率、死亡率、伤残调整寿命年(DALY)及其相应的年龄标化率的变化情况,通过Joinpoint软件进行回归分析,计算标化发病率、标化死亡率、标化DALY率的年度变化百分比(APC)和平均年度变化百分比(AAPC)以反映疾病负担变化趋势,并与全球数据进行比较。结果1990—2019年期间,我国NHL的疾病负担总体呈现上升趋势,与2019年相比,中国NHL标化发病率、标化死亡率、标化DALY率分别增长了144.72%、27.17%、15.61%。其年均变化率分别为3.12%、0.80%、0.51%。NHL疾病负担存在性别及年龄差异,随着年龄的增长疾病负担上升,男性高于女性。结论1990—2019年中国NHL的疾病负担呈现上升趋势,随着诊断与治疗方案发展,近几年疾病负担有所下降,但仍高于全球水平。对其发病机制及治疗方案仍需加强研究,对高危人群积极采取干预,以降低NHL的疾病负担。Objective To analyze the disease burden and development trend of non-Hodgkin lymphoma(NHL)in China from 1990 to 2019.Methods The changes of incidence,mortality,disability-adjusted life years(DALY)and their corresponding age-normalization rates for NHL were analyzed by using the 2019 Global Burden of Disease Database.Regression analysis was performed by Joinpoint software to calculate annual percentage change(APC)and average annual percentage change(AAPC)of standardized morbidity,standardized mortality,standardized DALY rate to reflect the change trend of disease burden.And the results were compared with global data.Results From 1990 to 2019,the disease burden of NHL in China showed an overall increasing trend.Compared with 2019,the standard incidence rate,standard mortality rate and standard DALY rate of NHL in China increased by 144.72%,27.17%and 15.61%,respectively.The annual rates of change were 3.12%,0.80%and 0.51%,respectively.There were gender and age differences in disease burden.The burden of disease increased with age,and the burden of disease was higher in males than in females.Conclusion The disease burden of NHL in China shows an increasing trend from 1990 to 2019.With the development of diagnosis and treatment options,the disease burden has decreased in recent years,but it is still higher than the global level.There is still a need to strengthen research on its pathogenesis and treatment options,and to actively intervene in high-risk groups to reduce the disease burden of NHL.

关 键 词：非霍奇金淋巴瘤 疾病负担 Joinpoint回归 伤残调整寿命年 

分 类 号：R733.1[医药卫生—肿瘤]